In this piece, we will look at where Moderna, Inc. (NASDAQ:MRNA) sits on the fund managers’ radar. The surge in interest ...

We recently published a list of 10 Best Depressed Stocks To Buy Heading into 2025. In this article, we are going to take a ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle ...

Zylem Biosciences announced that Northwestern University has filed a lawsuit against Moderna (MRNA), alleging infringement of key patents ...

The latest trading session saw Moderna (MRNA) ending at $53.80, denoting a -0.55% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.18%. Elsewhere, ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

TD Cowen analyst Tyler Van Buren has maintained their neutral stance on MRNA stock, giving a Hold rating on October 17. Tyler Van ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...